Multi-Target Therapy Helps Lupus Patients
Posted on: Thursday, 3 July 2008, 15:00 CDT
Chinese scientists say a treatment using several drugs targeting various parts of the immune system helps patients with severe lupus involving the kidneys.
In our study, multitarget therapy is shown to be superior to traditional therapy for inducing complete remission of class V+IV lupus nephritis, with few side effects, said Dr. Lei-Shi Li of the University School of Medicine in Nanjing, China.
Lupus nephritis is inflammation of the kidneys occurring in patients with systemic lupus erythematosus, or SLE. All patients had class V+IV disease, meaning widespread inflammation and decreasing kidney function.
The disease is traditionally treated with a single immunosuppressant drug, said Li, adding: We considered that, since the impact of severe SLE on the kidney involves various parts of the immune system, it is necessary to treat the different immune targets with a combination of immunosuppressant drugs.
Patients receiving the immunosuppressant drugs tacrolimus and mycophenolate mofetil, plus a steroid, showed complete remission, with recovery of normal kidney function about four times higher than conventionally treated patients. The complete remission rate reached 65 percent at nine months versus only 15 percent under traditional therapy, Li said.
The study appears in the Journal of the American Society of Nephrology.
Source: United Press International
Related Articles
- Organ Transplants Done Without Immune-suppressing Drugs
- Stanford Study Finds Transplant Patient Thrives Two Years After Stopping Immunosuppressive Drugs
- Isotechnika's Immunosuppressive Drug Found Safe in Animal Study
- Depression in Primary Caregivers of Patients Listed for Liver or Kidney Transplantation
- Trends in Therapeutic Monitoring of Immunosuppressive Drugs
- VELCADE(R) (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates As High As 54 Percent in Patients With Previously Treated Multiple Myeloma
- Isotechnika Receives Additional U.S. Patent for Lead Immunosuppressive Drug, ISA247
- Bone Marrow Transplant Patient Accepts New Kidney Without Taking Drugs
- Experimental Immunosuppressant Drug Lauded
- Pharmacogenetics As a Tool to Enable the Individualisation of Immunosuppressive Drug Treatment for Organ Transplantation
User Comments (0)
RSS Feeds